These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 19780597)
1. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues. Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597 [TBL] [Abstract][Full Text] [Related]
2. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. Malaisree M; Rungrotmongkol T; Decha P; Intharathep P; Aruksakunwong O; Hannongbua S Proteins; 2008 Jun; 71(4):1908-18. PubMed ID: 18175324 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317 [TBL] [Abstract][Full Text] [Related]
4. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations. Pan P; Li L; Li Y; Li D; Hou T Antiviral Res; 2013 Nov; 100(2):356-64. PubMed ID: 24055835 [TBL] [Abstract][Full Text] [Related]
5. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K. Tran-To Su C; Ouyang X; Zheng J; Kwoh CK BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719 [TBL] [Abstract][Full Text] [Related]
6. Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)". Rungrotmongkol T; Malaisree M; Udommaneethanakit T; Hannongbua S Biophys Chem; 2009 Apr; 141(1):131-2; author reply 133. PubMed ID: 19231807 [No Abstract] [Full Text] [Related]
7. Drugs against avian influenza a virus: design of novel sulfonate inhibitors of neuraminidase N1. Udommaneethanakit T; Rungrotmongkol T; Frecer V; Seneci P; Miertus S; Bren U Curr Pharm Des; 2014; 20(21):3478-87. PubMed ID: 24001233 [TBL] [Abstract][Full Text] [Related]
8. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses. Singh A; Soliman ME Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512 [TBL] [Abstract][Full Text] [Related]
9. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus. Park JW; Jo WH Eur J Med Chem; 2010 Feb; 45(2):536-41. PubMed ID: 19914748 [TBL] [Abstract][Full Text] [Related]
10. Neuraminidase inhibitor resistance in influenza viruses. Reece PA J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169 [TBL] [Abstract][Full Text] [Related]
11. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Hurt AC; Selleck P; Komadina N; Shaw R; Brown L; Barr IG Antiviral Res; 2007 Mar; 73(3):228-31. PubMed ID: 17112602 [TBL] [Abstract][Full Text] [Related]
12. Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach. Mai BK; Li MS Biochem Biophys Res Commun; 2011 Jul; 410(3):688-91. PubMed ID: 21693105 [TBL] [Abstract][Full Text] [Related]
13. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors. Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319 [TBL] [Abstract][Full Text] [Related]
14. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir. Park JW; Jo WH J Chem Inf Model; 2009 Dec; 49(12):2735-41. PubMed ID: 19957991 [TBL] [Abstract][Full Text] [Related]
15. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase. Liu H; Yao X; Wang C; Han J Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444 [TBL] [Abstract][Full Text] [Related]
16. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559 [TBL] [Abstract][Full Text] [Related]
17. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Du QS; Wang SQ; Chou KC Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775 [TBL] [Abstract][Full Text] [Related]
18. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442 [TBL] [Abstract][Full Text] [Related]
19. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. Malaisree M; Rungrotmongkol T; Nunthaboot N; Aruksakunwong O; Intharathep P; Decha P; Sompornpisut P; Hannongbua S Amino Acids; 2009 Oct; 37(4):725-32. PubMed ID: 19002747 [TBL] [Abstract][Full Text] [Related]
20. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Collins PJ; Haire LF; Lin YP; Liu J; Russell RJ; Walker PA; Skehel JJ; Martin SR; Hay AJ; Gamblin SJ Nature; 2008 Jun; 453(7199):1258-61. PubMed ID: 18480754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]